Risk factors of left ventricular hypertrophy in patients with non-dialysis chronic kidney disease

ZHANG Zhe; XIA Tian-yu; ZHANG Xiao-lin; LI Di; TAN Zhi-cheng

doi:10.3969/j.issn.1671-2390.2019.02.006

Journal of Clinical Nephrology > 2019 > 19(2): 107-111. > DOI: 10.3969/j.issn.1671-2390.2019.02.006

ZHANG Zhe, XIA Tian-yu, ZHANG Xiao-lin, LI Di, TAN Zhi-cheng. Risk factors of left ventricular hypertrophy in patients with non-dialysis chronic kidney disease[J]. Journal of Clinical Nephrology, 2019, 19(2): 107-111. DOI: 10.3969/j.issn.1671-2390.2019.02.006

Citation:

PDF (745 KB)

Risk factors of left ventricular hypertrophy in patients with non-dialysis chronic kidney disease

Department of Nephrolopy, the Second Affiliated Hospital of Shanxi Medial University, Taiyuan 030001, China

More Information

Received Date: August 19, 2018
Available Online: May 11, 2023
Published Date: February 27, 2019

Graphical Abstract

Abstract

Abstract

Objective To explore and analyze the risk factors of left ventricular hypertrophy (LVH) in patients with non-dialysis chronic kidney disease (ND-CKD), and to provide evidence for prevention of LVH in patients with ND-CKD. Methods The clinical data of 1001 ND-CKD patients who were admitted to the Second Hospital of Shanxi Medical University from January to May 2018 were collected. According to the occurrence of LVH, the patients were divided into LVH group (195 cases) and non-LVH group (806 cases). The clinical data of the two groups were compared. Logistic regression analysis was used to study the risk factors of LVH in ND-CKD patients. The ROC curve was used to study the predictive index of LVH in ND-CKD patients. Results Logistic regression analysis showed systolic blood pressure (OR=1.012), β₂-microglobulin (OR=0.939), total cholesterol (OR=1.183), homocysteine (OR=1.023), B-type natriuretic peptide (BNP) (OR=1.001) and erythrocyte sedimentation rate (OR=1.010) were independent risk factors of LVH in patients with ND-CKD. ROC curve analysis showed that BNP was good indicator for predicting LVH in patients with ND-CKD. Conclusions Early clinical intervention for risk factors of LVH may reduce or delay the onset of LVH and improve the prognosis of patients with CKD.
- Chronic kidney disease,
- Left ventricular hypertrophy,
- Ventricular remodeling,
- Risk factors

FullText(HTML)

References (26)

References

[1]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kindey disease in China:a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822.
[2]	Cai QZ, Lu XZ, Lu Y, et al. Longitudinal changes of cardiac structure and function in CKD (CASCADE study)[J]. J Am Soc Nephrol,2014, 25(7):1599-1608.
[3]	Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension[J]. Clin J Am Soc Nephrol, 2016, 11(2):271-279.
[4]	中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志, 2011, 3(5):42-93.
[5]	Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension:A report from the European Association of Cardiovascular Imaging(EACVI) and the American Society of Echocardiography(ASE)[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(6):577-605.
[6]	Dangri P, Agarwal S, Kalra OP, et al. Echocardiographic assessment of left ventricular hypertrophy in patients of chronic renal failure[J]. Indian J Nephrol, 2003, (13):92-97.
[7]	Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease[J]. Vasc Health Risk Manag, 2009, (5):713-722.
[8]	Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease:Comparison of traditional and novel risk factors[J]. JAMA, 2005, 293(14):1737-1745.
[9]	Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD[J]. Am J Kidney Dis, 2005, 46(2):320-327.
[10]	Colbert G, Jain N, de Lemos JA, et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD[J]. Clin J Am Soc Nephrol, 2015, 10(3):515-529.
[11]	Bregman R, Lemos C, Pecoits Filho R, et al. Left ventricular hypertrophy in patients with chronic kidney disease under conservative treatment[J]. J Bras Nefrol,2010, 32(1):83-88.
[12]	Nitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease[J]. Clin Exp Nephrol, 2013, 17(5):730-742.
[13]	Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease:Why is it so resistant to treatment?[J]. Kidney Int, 2006, 69(6):967-973.
[14]	Soliman EZ, Byington RP, Bigger JT, et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus:Action to control cardiovascular risk in diabetes blood pressure trial[J]. Hypertension, 2015, 66(6):1123-1129.
[15]	Ye Z, Zhang Q, Li Y, et al. High prevalence of hyperhomocysteinemia and its association with target organ damage in chinese patients with chronic kidney disease[J]. Nutrients, 2016, 8(10), 645.
[16]	Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD:An in-depth review[J]. Adv Ren Replace Ther, 2003, 10(4):279-309.
[17]	Liabeuf S, Lenglet A, Desjardins L, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients[J]. Kidney Int, 2012, 82(12):1297-1303.
[18]	Vianello A, Caponi L, Galetta F, et al. β₂-microglobulin and TIMP1 are linked together in cardiorenal remodeling and failure[J]. Cardiorenal Med, 2015, 5(1):1-11.
[19]	Viana Gonçalves IC, Cerdeira CD, Poletti Camara E, et al. Tempol improves lipid profile and prevents left ventricular hypertrophy in LDL receptor gene knockout (LDLr-/-) mice under a high-fat diet[J]. Rev Port Cardiol, 2017, 36(9):629-638.
[20]	Wu PY, Huang JC, Chen SC, et al. Type 2 diabetes mellitus-related changes in left ventricular structure and function in patients with chronic kidney disease[J]. Oncotarget, 2018, 9(18):14661-14668.
[21]	Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction[J]. Circulation, 1995, 92(6):1558-1564.
[22]	DeFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis[J]. Am J Kidney Dis, 2005, 46(1):35-44.
[23]	Mishra RK, Li Y, Ricardo AC, et al. Chronic renal insufficiency cohort investigators:Association of n-terminal pro-b-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the chronic renal insufficiency cohort[CRIC])[J]. Am J Cardiol, 2013, 111(3):432-438.
[24]	Yang Y, Wang Y, Shi ZW, et al. Association of E/E' and NT-proBNP with renal function in patients with essential hypertension[J]. PLoS ONE, 2013, 8(1):e54513.
[25]	Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease[J]. Eur Heart J, 2011, 32(1):84-92.
[26]	Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease[J]. Kidney Int, 2010, 77(6):550-556.

Cited By

Get Citation

PDF

XML

Article views (367) PDF downloads (294)

Turn off MathJax

Article Contents

Abstract

References

Risk factors of left ventricular hypertrophy in patients with non-dialysis chronic kidney disease

Abstract

References

Catalog

Export File

Citation

Format

Content